Exact Mass: 451.1478
Exact Mass Matches: 451.1478
Found 466 metabolites which its exact mass value is equals to given mass value 451.1478
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Doxazosin
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Flucythrinate
(1R)-Hydroxy-(2R)-glutathionyl-1,2-dihydronaphthalene
This compound belongs to the family of Peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
(1R)-Glutathionyl-(2R)-hydroxy-1,2-dihydronaphthalene
This compound belongs to the family of Peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
(1S)-Hydroxy-(2S)-glutathionyl-1,2-dihydronaphthalene
This compound belongs to the family of Peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
5-O-Feruloylnigrumin
5-O-Feruloylnigrumin is found in fruits. 5-O-Feruloylnigrumin is a constituent of the seeds of Ribes nigrum (blackcurrant). Constituent of the seeds of Ribes nigrum (blackcurrant). 5-O-Feruloylnigrumin is found in fruits.
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
4-Hydroxypropranolol glucuronide
Betrixaban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins
4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-
Rigosertib
Succinyl-trialanine-4-nitroanilide
D-Phenylalanine, 4-fluoro-N-(((5-(4-fluorophenyl)-2-benzofuranyl)methoxy)carbonyl)-
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
(4E)-5-{6-O-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-beta-glucopyranosylsulfanyl}pent-4-enenitrile
(1S,4R)-1-(beta-D-Glucopyranosyloxy)-4-(6-deoxy-beta-D-gulopyranosyloxy)-2-cyclopentene-1-carboxamide
doxazosin
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293
Ala Cys Cys Arg
Ala Cys Lys Met
Ala Cys Met Lys
Ala Cys Met Gln
Ala Cys Gln Met
Ala Cys Arg Cys
Ala Lys Cys Met
Ala Lys Met Cys
Ala Met Cys Lys
Ala Met Cys Gln
Ala Met Lys Cys
Ala Met Gln Cys
Ala Gln Cys Met
Ala Gln Met Cys
Ala Arg Cys Cys
Cys Ala Cys Arg
Cys Ala Lys Met
Cys Ala Met Lys
Cys Ala Met Gln
Cys Ala Gln Met
Cys Ala Arg Cys
Cys Cys Ala Arg
Cys Cys Ile Asn
Cys Cys Lys Val
Cys Cys Leu Asn
Cys Cys Asn Ile
Cys Cys Asn Leu
Cys Cys Gln Val
Cys Cys Arg Ala
Cys Cys Val Lys
Cys Cys Val Gln
Cys Asp Lys Ser
Cys Asp Asn Thr
Cys Asp Gln Ser
Cys Asp Ser Lys
Cys Asp Ser Gln
Cys Asp Thr Asn
Cys Glu Asn Ser
Cys Glu Ser Asn
Cys Gly Ser Trp
Cys Gly Trp Ser
Cys Ile Cys Asn
Cys Ile Asn Cys
Cys Lys Ala Met
Cys Lys Cys Val
Cys Lys Asp Ser
Cys Lys Met Ala
Cys Lys Ser Asp
Cys Lys Val Cys
Cys Leu Cys Asn
Cys Leu Asn Cys
Cys Met Ala Lys
Cys Met Ala Gln
Cys Met Lys Ala
Cys Met Gln Ala
Cys Asn Cys Ile
Cys Asn Cys Leu
Cys Asn Asp Thr
Cys Asn Glu Ser
Cys Asn Ile Cys
Cys Asn Leu Cys
Cys Asn Ser Glu
Cys Asn Thr Asp
Cys Gln Ala Met
Cys Gln Cys Val
Cys Gln Asp Ser
Cys Gln Met Ala
Cys Gln Ser Asp
Cys Gln Thr Thr
Cys Gln Val Cys
Cys Arg Ala Cys
Cys Arg Cys Ala
Cys Arg Ser Ser
Cys Ser Asp Lys
Cys Ser Asp Gln
Cys Ser Glu Asn
Cys Ser Gly Trp
Cys Ser Lys Asp
Cys Ser Asn Glu
Cys Ser Gln Asp
Cys Ser Arg Ser
Cys Ser Ser Arg
Cys Ser Trp Gly
Cys Thr Asp Asn
Cys Thr Asn Asp
Cys Thr Gln Thr
Cys Thr Thr Gln
Cys Val Cys Lys
Cys Val Cys Gln
Cys Val Lys Cys
Cys Val Gln Cys
Cys Trp Gly Ser
Cys Trp Ser Gly
Asp Cys Lys Ser
Asp Cys Asn Thr
Asp Cys Gln Ser
Asp Cys Ser Lys
Asp Cys Ser Gln
Asp Cys Thr Asn
Asp Phe Gly Asn
Asp Phe Asn Gly
Asp Gly Phe Asn
Asp Gly Asn Phe
Asp Lys Cys Ser
Asp Lys Ser Cys
Asp Asn Cys Thr
Asp Asn Phe Gly
Asp Asn Gly Phe
Asp Asn Thr Cys
Asp Gln Cys Ser
Asp Gln Ser Cys
Asp Ser Cys Lys
Asp Ser Cys Gln
Asp Ser Lys Cys
Asp Ser Gln Cys
Asp Thr Cys Asn
Asp Thr Asn Cys
Glu Cys Asn Ser
Glu Cys Ser Asn
Glu Asn Cys Ser
Glu Asn Ser Cys
Glu Ser Cys Asn
Glu Ser Asn Cys
Phe Asp Gly Asn
Phe Asp Asn Gly
Phe Gly Asp Asn
Phe Gly Asn Asp
Phe Asn Asp Gly
Phe Asn Gly Asp
Gly Cys Ser Trp
Gly Cys Trp Ser
Gly Asp Phe Asn
Gly Asp Asn Phe
Gly Phe Asp Asn
Gly Phe Asn Asp
Gly Met Met Asn
Gly Met Asn Met
Gly Asn Asp Phe
Gly Asn Phe Asp
Gly Asn Met Met
Gly Ser Cys Trp
Gly Ser Trp Cys
Gly Trp Cys Ser
Gly Trp Ser Cys
Ile Cys Cys Asn
Ile Cys Asn Cys
Ile Asn Cys Cys
Lys Ala Cys Met
Lys Ala Met Cys
Lys Cys Ala Met
Lys Cys Cys Val
Lys Cys Asp Ser
Lys Cys Met Ala
Lys Cys Ser Asp
Lys Cys Val Cys
Lys Asp Cys Ser
Lys Asp Ser Cys
Lys Met Ala Cys
Lys Met Cys Ala
Lys Ser Cys Asp
Lys Ser Asp Cys
Lys Val Cys Cys
Leu Cys Cys Asn
Leu Cys Asn Cys
Leu Asn Cys Cys
Met Ala Cys Lys
Met Ala Cys Gln
Met Ala Lys Cys
Met Ala Gln Cys
Met Cys Ala Lys
Met Cys Ala Gln
Met Cys Lys Ala
Met Cys Gln Ala
Met Gly Met Asn
Met Gly Asn Met
Met Lys Ala Cys
Met Lys Cys Ala
Met Met Gly Asn
Met Met Asn Gly
Met Asn Gly Met
Met Asn Met Gly
Met Asn Ser Thr
Met Asn Thr Ser
Met Gln Ala Cys
Met Gln Cys Ala
Met Gln Ser Ser
Met Ser Asn Thr
Met Ser Gln Ser
Met Ser Ser Gln
Met Ser Thr Asn
Met Thr Asn Ser
Met Thr Ser Asn
Asn Cys Cys Ile
Asn Cys Cys Leu
Asn Cys Asp Thr
Asn Cys Glu Ser
Asn Cys Ile Cys
Asn Cys Leu Cys
Asn Cys Ser Glu
Asn Cys Thr Asp
Asn Asp Cys Thr
Asn Asp Phe Gly
Asn Asp Gly Phe
Asn Asp Thr Cys
Asn Glu Cys Ser
Asn Glu Ser Cys
Asn Phe Asp Gly
Asn Phe Gly Asp
Asn Gly Asp Phe
Asn Gly Phe Asp
Asn Gly Met Met
Asn Ile Cys Cys
Asn Leu Cys Cys
Asn Met Gly Met
Asn Met Met Gly
Asn Met Ser Thr
Asn Met Thr Ser
Asn Ser Cys Glu
Asn Ser Glu Cys
Asn Ser Met Thr
Asn Ser Thr Met
Asn Thr Cys Asp
Asn Thr Asp Cys
Asn Thr Met Ser
Asn Thr Ser Met
Gln Ala Cys Met
Gln Ala Met Cys
Gln Cys Ala Met
Gln Cys Cys Val
Gln Cys Asp Ser
Gln Cys Met Ala
Gln Cys Ser Asp
Gln Cys Thr Thr
Gln Cys Val Cys
Gln Asp Cys Ser
Gln Asp Ser Cys
Gln Met Ala Cys
Gln Met Cys Ala
Gln Met Ser Ser
Gln Ser Cys Asp
Gln Ser Asp Cys
Gln Ser Met Ser
Gln Ser Ser Met
Gln Thr Cys Thr
Gln Thr Thr Cys
Gln Val Cys Cys
Arg Ala Cys Cys
Arg Cys Ala Cys
Arg Cys Cys Ala
Arg Cys Ser Ser
Arg Ser Cys Ser
Arg Ser Ser Cys
Ser Cys Asp Lys
Ser Cys Asp Gln
Ser Cys Glu Asn
Ser Cys Gly Trp
Ser Cys Lys Asp
Ser Cys Asn Glu
Ser Cys Gln Asp
Ser Cys Arg Ser
Ser Cys Ser Arg
Ser Cys Trp Gly
Ser Asp Cys Lys
Ser Asp Cys Gln
Ser Asp Lys Cys
Ser Asp Gln Cys
Ser Glu Cys Asn
Ser Glu Asn Cys
Ser Gly Cys Trp
Ser Gly Trp Cys
Ser Lys Cys Asp
Ser Lys Asp Cys
Ser Met Asn Thr
Ser Met Gln Ser
Ser Met Ser Gln
Ser Met Thr Asn
Ser Asn Cys Glu
Ser Asn Glu Cys
Ser Asn Met Thr
Ser Asn Thr Met
Ser Gln Cys Asp
Ser Gln Asp Cys
Ser Gln Met Ser
Ser Gln Ser Met
Ser Arg Cys Ser
Ser Arg Ser Cys
Ser Ser Cys Arg
Ser Ser Met Gln
Ser Ser Gln Met
Ser Ser Arg Cys
Ser Thr Met Asn
Ser Thr Asn Met
Ser Trp Cys Gly
Ser Trp Gly Cys
Thr Cys Asp Asn
Thr Cys Asn Asp
Thr Cys Gln Thr
Thr Cys Thr Gln
Thr Asp Cys Asn
Thr Asp Asn Cys
Thr Met Asn Ser
Thr Met Ser Asn
Thr Asn Cys Asp
Thr Asn Asp Cys
Thr Asn Met Ser
Thr Asn Ser Met
Thr Gln Cys Thr
Thr Gln Thr Cys
Thr Ser Met Asn
Thr Ser Asn Met
Thr Thr Cys Gln
Thr Thr Gln Cys
Val Cys Cys Lys
Val Cys Cys Gln
Val Cys Lys Cys
Val Cys Gln Cys
Val Lys Cys Cys
Val Gln Cys Cys
Trp Cys Gly Ser
Trp Cys Ser Gly
Trp Gly Cys Ser
Trp Gly Ser Cys
Trp Ser Cys Gly
Trp Ser Gly Cys
5-O-Feruloylnigrumin
4-FORMYLPHENYL 2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-β-D-GLUCOPYRANOSIDE
Rigosertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents
4-DAMP
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
4-(p-dimethylaminophenyl)-2,6-diphenylpyrylium perchlorate
4-methylumbelliferyl a-l-idopyranosiduronic acid, cyclohexylammonium salt
(5S,6R)-6-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-5-(4-fluorophenyl)-3-morpholinone
(R)-2-((1R)-3-benzyl-7-oxo-(1rH,5cH)-4-thia-2,6-diaza-bicyclo[3.2.0]hept-2-en-6-yl)-3-methyl-but-3-enoic acid 4-nitro-benzyl ester
disodium 4-[2-[(1-oxoundec-10-enyl)amino]ethyl] 2-sulphonatosuccinate
Ethanone, 1-(4-(4-chloro-3-methoxyphenyl)-1-piperazinyl)-2-(3-(1H-imidazol-2-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)-
4-(4-Chloro-phenyl)-1-{3-[2-(4-fluoro-phenyl)-[1,3]dithiolan-2-YL]-propyl}-piperidin-4-OL
Dihydrocodeine bitartrate
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
Stilonium iodide
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
Piritrexim isethionate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor
cyano(3-phenoxyphenyl)methyl (2S)-2-[4-(difluoromethoxy)phenyl]-3-methylbutanoate
N-[2,6-dimethyl-3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N,4-dimethylbenzenesulfonamide
2-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-D]pyrimidin-5-YL)-ethyl]-benzoylamino}-4-(2H-tetrazol-5-YL)-butyric acid
Betrixaban
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
(E)-1-(glutathion-S-yl)-N-hydroxy-omega-(methylsulfanyl)pentan-1-imine
7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione
10-(3-Carboxypropyl)-3,6-bis(dimethylamino)acridinium perchlorate
N-[4-[[4-(4-methylphenyl)sulfonyl-1,4-diazepan-1-yl]sulfonyl]phenyl]acetamide
6-[(2-ethylphenyl)sulfamoyl]-N-(2-furanylmethyl)-4-oxo-1H-quinoline-3-carboxamide
3-(4-fluorophenyl)-1-[(6-oxo-5H-[1,3]dioxolo[4,5-g]quinolin-7-yl)methyl]-1-(thiophen-2-ylmethyl)urea
1-(3-Methoxyphenyl)-2-[[4-methyl-5-[[(4-phenyl-2-thiazolyl)amino]methyl]-1,2,4-triazol-3-yl]thio]ethanone
ethyl 4-{[(2E)-2-(3-methylbenzylidene)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl]carbonyl}piperazine-1-carboxylate
1-[(8R,9R,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzenesulfonamide
2-[(2R,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2S,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2S,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)oxan-2-yl]-N-(2-pyridin-4-ylethyl)acetamide
N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2R,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2S,3R,6S)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide
2-[(1S,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3R,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
1-[(8R,9S,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
1-[(8S,9R,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
1-[(8S,9S,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
2-[(2S,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2R,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2S,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2R,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
2-[(2R,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide
N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide
N-[(2R,3S,6R)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide
N-[(2S,3R,6R)-6-[2-[(3-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(2-pyridinyl)acetamide
2-[(1R,3R,4aR,9aS)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1S,3R,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
2-[(1R,3S,4aS,9aR)-6-[(4-fluorophenyl)sulfonylamino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester
1-[(8S,9R,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
1-[(8S,9S,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
1-[(8R,9R,10S)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
1-[(8R,9S,10R)-9-(4-bromophenyl)-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]-2-(4-morpholinyl)ethanone
Lysidine monophosphate
A pyrimidine ribonucleoside 5-monophosphate that is CMP in which the 2-keto group on the cytosine ring is replaced by an epsilon-L-lysyl residue.
(5Z)-5-[(1-Benzyl-3,4-dihydro-2H-quinolin-6-yl)methylidene]-1-(2-methylphenyl)-1,3-diazinane-2,4,6-trione
(1R)-Hydroxy-(2R)-glutathionyl-1,2-dihydronaphthalene
(1R)-Glutathionyl-(2R)-hydroxy-1,2-dihydronaphthalene
(1S)-Hydroxy-(2S)-glutathionyl-1,2-dihydronaphthalene
Flucythrinate
4-[[2-[(3-methylphenyl)methylidene]-3-oxo-4H-1,4-benzothiazin-6-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester
PRGL493
PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research[1].